Sebastiaan J. Vastert

Treating juvenile idiopathic arthritis to target: recommendations of an international task force

Angelo Ravelli, Alessandro Consolaro, Gerd Horneff et al. · Annals of the Rheumatic Diseases · 2018 · 357 citations · Full text

Medicine, Clinical Sciences, Pediatrics +13

Effectiveness of First‐Line Treatment With Recombinant Interleukin‐1 Receptor Antagonist in Steroid‐Naive Patients With New‐Onset Systemic Juvenile Idiopathic Arthritis: Results of a Prospective Cohort Study

Sebastiaan J. Vastert, Wilco de Jager, Bo Jan Noordman et al. · Arthritis & Rheumatology · 2013 · 263 citations

Life Sciences, Immunology, Pharmacotherapy +14

Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis

Sebastiaan J. Vastert, Richard van Wijk, Leila Emma D’Urbano et al. · Lara D. Veeken · 2009 · 229 citations · Full text

Life Sciences, Genetics, Immunology +13

A phase II, multicenter, open‐label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features

Nicolino Ruperto, Pierre Quartier, Nico Wulffraat et al. · Arthritis & Rheumatism · 2011 · 193 citations

Medicine, Pediatrics, Pharmacotherapy +9

Treatment to Target Using Recombinant Interleukin‐1 Receptor Antagonist as First‐Line Monotherapy in New‐Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five‐Year Follow‐Up Study

Nienke M. ter Haar, E. H. Pieter van Dijkhuizen, Joost F. Swart et al. · Arthritis & Rheumatology · 2019 · 186 citations · Full text

Medicine, Immunology, Pharmacotherapy +16